Navigating the New Disclosure and Policy Requirements in Response to the SEC’s Clawback Rule

The SEC issued a final rule on October 26, 2022, Listing Standards for Recovery of Erroneously Awarded Compensation (commonly referred to as the “Clawback Rule”), to prevent executive officers from retaining excess compensation following an accounting restatement.

More

Assessing SEC Filing Status and Qualifications

Under the Securities Exchange Act of 1934, the SEC classifies publicly traded companies by their filing status (i.

More

2023 Financial Statement Filing Deadlines and Staleness Calendar

Planning for a registration statement includes assessing which financial statements are required to be included.

More

Zombie SPACs and Blood Baths

<

More

The Future Is Already Here, and CFOs Need to Transform Finance to Survive

Download the Whitepaper

Third Harmonic Bio Closes Upsized Initial Public Offering of Shares of Common Stock Trading on the NASDAQ Global Market

CFGI’s Life Sciences team assisted Third Harmonic Bio (NASDAQ: THRD) with their initial public offering.

More

Senti Biosciences Completes Merger With Dynamics Special Purpose Corp.

CFGI’s Capital Markets team assisted Senti Biosciences, Incorporated (“Senti Bio”) with the completion of its merger with Dynamics Special Purpose Corporation (“DYNS”) (Nasdaq: DYNS), a special purpose acquisition company.

More

BCP Raptor Holdco LP Completes Reverse Merger With Altus Midstream Company

CFGI’s Capital Markets team assisted privately-owned BCP Raptor Holdco LP (“BCP”), the parent company of EagleClaw Midstream, with the completion of an all-stock business combination with Altus Midstream Company (Nasdaq: ALTM) (“Altus”), creating a unique, fully-integrated midstream company.

More

Capital Markets Advisory: 2021 Year in Review

2021 was an exciting year of growth for CFGI, which included a new partnership with CVC Capital Partners, one of the world’s largest private equity firms.

More